Last edition
News about "TL1A antibody "
AbbVie and FutureGen to Develop Next-Gen Therapy for Inflammatory Bowel Disease
AbbVie has signed a license agreement with FutureGen Biopharmaceutical to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.
TL1A Antibody | 14/06/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members